Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®
Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A RomijnDepartment of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The NetherlandsBackground: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is ass...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e129be341b1540a8bdfabf329e5c5f9b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e129be341b1540a8bdfabf329e5c5f9b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e129be341b1540a8bdfabf329e5c5f9b2021-12-02T08:43:47ZTherapeutic options in the management of acromegaly: focus on lanreotide Autogel®1177-54751177-5491https://doaj.org/article/e129be341b1540a8bdfabf329e5c5f9b2008-09-01T00:00:00Zhttp://www.dovepress.com/therapeutic-options-in-the-management-of-acromegaly-focus-on-lanreotid-a2296https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A RomijnDepartment of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The NetherlandsBackground: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.Objective: To delineate the role of lanreotide in the treatment of acromegaly.Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.Keywords: acromegaly, lanreotide, somatostatin analog, growth hormone, pegvisomant FerdinRoelfsemaNienke R BiermaszAlberto M PereiraJohannes A RomijnDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 463-479 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Ferdin Roelfsema Nienke R Biermasz Alberto M Pereira Johannes A Romijn Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| description |
Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A RomijnDepartment of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The NetherlandsBackground: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.Objective: To delineate the role of lanreotide in the treatment of acromegaly.Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.Keywords: acromegaly, lanreotide, somatostatin analog, growth hormone, pegvisomant |
| format |
article |
| author |
Ferdin Roelfsema Nienke R Biermasz Alberto M Pereira Johannes A Romijn |
| author_facet |
Ferdin Roelfsema Nienke R Biermasz Alberto M Pereira Johannes A Romijn |
| author_sort |
Ferdin |
| title |
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| title_short |
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| title_full |
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| title_fullStr |
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| title_full_unstemmed |
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® |
| title_sort |
therapeutic options in the management of acromegaly: focus on lanreotide autogel® |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/e129be341b1540a8bdfabf329e5c5f9b |
| work_keys_str_mv |
AT ferdin therapeuticoptionsinthemanagementofacromegalyfocusonlanreotideautogelampreg AT roelfsema therapeuticoptionsinthemanagementofacromegalyfocusonlanreotideautogelampreg AT nienkerbiermasz therapeuticoptionsinthemanagementofacromegalyfocusonlanreotideautogelampreg AT albertompereira therapeuticoptionsinthemanagementofacromegalyfocusonlanreotideautogelampreg AT johannesaromijn therapeuticoptionsinthemanagementofacromegalyfocusonlanreotideautogelampreg |
| _version_ |
1718398437422006272 |